David Goodrich, PhD of Roswell Park Cancer Institute, Department of Pharmacology and Therapeutics discusses his hopes for new targets to treat Androgen Deprivation Therapy (ADT) Resistant Disease. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.
Hopes for Targets to Treat ADT Resistant Disease
